ly 293558 has been researched along with pyrrolidine-2,4-dicarboxylic acid in 1 studies
| Studies (ly 293558) | Trials (ly 293558) | Recent Studies (post-2010) (ly 293558) | Studies (pyrrolidine-2,4-dicarboxylic acid) | Trials (pyrrolidine-2,4-dicarboxylic acid) | Recent Studies (post-2010) (pyrrolidine-2,4-dicarboxylic acid) |
|---|---|---|---|---|---|
| 103 | 4 | 18 | 190 | 0 | 16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McGinty, JF; Rawls, SM | 1 |
1 other study(ies) available for ly 293558 and pyrrolidine-2,4-dicarboxylic acid
| Article | Year |
|---|---|
L-trans-pyrrolidine-2,4-dicarboxylic acid-evoked striatal glutamate levels are attenuated by calcium reduction, tetrodotoxin, and glutamate receptor blockade.
Topics: Animals; Calcium; Chromatography, High Pressure Liquid; Dicarboxylic Acids; Excitatory Amino Acid Antagonists; Glutamic Acid; Isoquinolines; Male; Microdialysis; Neostriatum; Neurotransmitter Uptake Inhibitors; Oxidation-Reduction; Piperazines; Pyrrolidines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tetrazoles; Tetrodotoxin | 1997 |